BACKGROUND: Peritoneal dialysis (PD) is an established treatment modality for end-stage renal disease (ESRD). Peritonitis remains a serious complication in PD patients and an important cause of drop-out from the program. Types of pathogens and their drug resistance patterns may determine the outcome of peritonitis. The present study was undertaken to determine the microbiology of peritonitis in PD patients, antibiotic resistance in commonly isolated bacterial pathogens and clinical outcomes. METHOD: We enrolled 211 patients with ESRD undergoing PD who developed peritonitis during 2002 to 2011. PD fluids were cultured and antibiotic susceptibility test of the bacterial isolates was performed. RESULT: A total of 303 peritonitis episodes with an overall incidence of 0.41 episodes per patient-year were recorded. Gram-positive, gram-negative, fungi, Mycobacterium tuberculosis and ≥ 2 organisms were isolated from 102 (33.7%), 89 (29.4%), 41 (13.5%), 11 (3.6%) and five (1.6%) episodes respectively; 55 (18.2%) episodes were culture negative. Coagulase-negative Staphylococcus spp. (CONS) was the most common isolate. Catheter loss and hospital admission in gram-negative peritonitis were significantly higher than in gram-positive peritonitis (36/89 (40.4%) vs 20/102 (19.6%), p < 0.001; and 56/89 (62.9%) vs 42/102 (41.2%), p = 0.004 respectively). Antibiotic susceptibility tests showed 54.3% of Enterobacteriaceae isolates were extended spectrum β-lactamase (ESBL) producers, 23.5% of Acinetobacter species and 11.5% of Pseudomonas aeruginosa were metallo-β-lactamase (MBL) producers; 15.4% of enterococci and 28.6% of staphylococci were resistant to vancomycin and methicillin respectively. Mortality was significantly higher in patients having peritonitis due to vancomycin-resistant enterococci, ESBL- and MBL-producing bacteria. CONCLUSION: Emerging antimicrobial resistance calls for prompt diagnosis and aggressive empiric therapy based on the local sensitivity data.
BACKGROUND: Peritoneal dialysis (PD) is an established treatment modality for end-stage renal disease (ESRD). Peritonitis remains a serious complication in PDpatients and an important cause of drop-out from the program. Types of pathogens and their drug resistance patterns may determine the outcome of peritonitis. The present study was undertaken to determine the microbiology of peritonitis in PDpatients, antibiotic resistance in commonly isolated bacterial pathogens and clinical outcomes. METHOD: We enrolled 211 patients with ESRD undergoing PD who developed peritonitis during 2002 to 2011. PD fluids were cultured and antibiotic susceptibility test of the bacterial isolates was performed. RESULT: A total of 303 peritonitis episodes with an overall incidence of 0.41 episodes per patient-year were recorded. Gram-positive, gram-negative, fungi, Mycobacterium tuberculosis and ≥ 2 organisms were isolated from 102 (33.7%), 89 (29.4%), 41 (13.5%), 11 (3.6%) and five (1.6%) episodes respectively; 55 (18.2%) episodes were culture negative. Coagulase-negative Staphylococcus spp. (CONS) was the most common isolate. Catheter loss and hospital admission in gram-negative peritonitis were significantly higher than in gram-positive peritonitis (36/89 (40.4%) vs 20/102 (19.6%), p < 0.001; and 56/89 (62.9%) vs 42/102 (41.2%), p = 0.004 respectively). Antibiotic susceptibility tests showed 54.3% of Enterobacteriaceae isolates were extended spectrum β-lactamase (ESBL) producers, 23.5% of Acinetobacter species and 11.5% of Pseudomonas aeruginosa were metallo-β-lactamase (MBL) producers; 15.4% of enterococci and 28.6% of staphylococci were resistant to vancomycin and methicillin respectively. Mortality was significantly higher in patients having peritonitis due to vancomycin-resistant enterococci, ESBL- and MBL-producing bacteria. CONCLUSION: Emerging antimicrobial resistance calls for prompt diagnosis and aggressive empiric therapy based on the local sensitivity data.
Entities:
Keywords:
Antibiotic resistance; etiology of peritonitis; mortality in peritonitis; outcome of peritonitis; peritoneal dialysis
Authors: Sai Ram Keithi-Reddy; Krishan L Gupta; Vivekanand Jha; Kamal Sud; Shrawan K Singh; Harbir S Kohli; Vinay Sakhuja Journal: Perit Dial Int Date: 2007 Mar-Apr Impact factor: 1.756
Authors: Pasqual Barretti; Daniel Pereira; Maria Aparecida Brasil; Maria de Lourdes Cunha; Jacqueline Caramori; Augusto Montelli Journal: Perit Dial Int Date: 2009 Mar-Apr Impact factor: 1.756
Authors: Miguel Pérez Fontan; Ana Rodríguez-Carmona; Rafael García-Naveiro; Miguel Rosales; Pedro Villaverde; Francisco Valdés Journal: Perit Dial Int Date: 2005 May-Jun Impact factor: 1.756
Authors: Narayan Prasad; Amit Gupta; Raj K Sharma; Kashi N Prasad; Sanjeev Gulati; Ajay P Sharma Journal: Perit Dial Int Date: 2003-12 Impact factor: 1.756
Authors: C-C Szeto; V C-Y Chow; K-M Chow; R W-M Lai; K-Y Chung; C-B Leung; B C-H Kwan; P K-T Li Journal: Kidney Int Date: 2006-04 Impact factor: 10.612
Authors: Lei Zhang; Sunil V Badve; Elaine M Pascoe; Elaine Beller; Alan Cass; Carolyn Clark; Janak de Zoysa; Nicole M Isbel; Steven McTaggart; Alicia T Morrish; E Geoffrey Playford; Anish Scaria; Paul Snelling; Liza A Vergara; Carmel M Hawley; David W Johnson Journal: Perit Dial Int Date: 2015-07-29 Impact factor: 1.756
Authors: Terry King-Wing Ma; Chi Bon Leung; Kai Ming Chow; Bonnie Ching-Ha Kwan; Philip Kam-Tao Li; Cheuk Chun Szeto Journal: Clin Kidney J Date: 2016-07-04
Authors: Carolina F F A Costa; Ana Merino-Ribas; Catarina Ferreira; Carla Campos; Nádia Silva; Luciano Pereira; Andreia Garcia; Álvaro Azevedo; Raquel B R Mesquita; António O S S Rangel; Célia M Manaia; Benedita Sampaio-Maia Journal: Front Microbiol Date: 2021-12-14 Impact factor: 5.640
Authors: Ana Cláudia Moro Lima Dos Santos; Aydir Cecília Marinho Monteiro; Thaís Alves Barbosa; Danilo Flávio Moraes Riboli; Carlos Henrique Camargo; Adriano Martison Ferreira; Alessandro Lia Mondelli; Augusto Cezar Montelli; Rodrigo Tavanelli Hernandes; Maria de Lourdes Ribeiro de Souza da Cunha; Pasqual Barretti Journal: Pathogens Date: 2022-02-08